{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:12:32Z","timestamp":1789193552766,"version":"build-2803163510"},"publisher-location":"Dordrecht","reference-count":105,"publisher":"Springer Netherlands","isbn-type":[{"value":"9781402056871","type":"print"},{"value":"9781402056888","type":"electronic"}],"license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007]]},"DOI":"10.1007\/1-4020-5688-5_9","type":"book-chapter","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T00:38:54Z","timestamp":1178584734000},"page":"193-212","source":"Crossref","is-referenced-by-count":79,"title":["Cancer Chemoprevention by Cyclooxygenase 2 (COX-2) Blockade"],"prefix":"10.1007","author":[{"given":"Randall E.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Beebe-Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galal A.","family":"Alshafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"2","key":"9_CR1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"J Ahmedin","year":"2006","unstructured":"Ahmedin J, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA Cancer J Clin 56 (2): 106\u2013130, 2006.","journal-title":"CA Cancer J Clin"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1385\/1-59259-302-X:341","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"RE Harris","year":"2002","unstructured":"Harris RE. COX-2 blockade in cancer prevention and therapy: widening the scope of impact. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 341\u2013365, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR3","first-page":"559","volume":"13","author":"RE Harris","year":"2005","unstructured":"Harris RE, Beebe-Donk J, Doss H, Burr-Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncology Reports 13: 559\u2013583, 2005.","journal-title":"Oncology Reports"},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-3-28","volume":"3","author":"A Gonzalez-Perez","year":"2003","unstructured":"Gonzalez-Perez A, Garcia Rodriquez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3: 1\u201312, 2003.","journal-title":"BMC Cancer"},{"key":"9_CR5","first-page":"323","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 323\u2013235, 1971.","journal-title":"Nature"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00666095","volume":"13","author":"HR Herschman","year":"1994","unstructured":"Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer and Metas Rev 13: 241\u2013256, 1994.","journal-title":"Cancer and Metas Rev"},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1073\/pnas.89.16.7384","volume":"89","author":"T Hla","year":"1992","unstructured":"Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384\u20137388, 1992.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"9_CR8","first-page":"4997","volume":"58","author":"H Wolff","year":"1998","unstructured":"Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (22): 4997\u201350, 1998.","journal-title":"Cancer Res"},{"key":"9_CR9","first-page":"198","volume":"59","author":"T Hida","year":"1999","unstructured":"Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cylcooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 59: 198\u2013204, 1999.","journal-title":"Cancer Res"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","volume":"107","author":"CE Eberhart","year":"1994","unstructured":"Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cycloxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183\u20131188, l994.","journal-title":"Gastroenterology"},{"key":"9_CR11","first-page":"503","volume":"10","author":"ML Parrett","year":"1997","unstructured":"Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology 10: 503\u2013507, 1997.","journal-title":"International Journal of Oncology"},{"issue":"5","key":"9_CR12","first-page":"1306","volume":"60","author":"JL Masferrer","year":"2000","unstructured":"Masferrer JL, Leahy KM, Koki AT, Aweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (5): 1306\u20131311, 2000.","journal-title":"Cancer Res"},{"key":"9_CR13","first-page":"3785","volume":"55","author":"H Sano","year":"1995","unstructured":"Sano H, Kawahito Y, Wilder R, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785\u20133789, 1995.","journal-title":"Cancer Res"},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1385\/1-59259-302-X:185","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"AT Koki","year":"2002","unstructured":"Koki AT, Leahy KM, Harmon JM, Masferrer JL. Cyclooxygenase-2 and cancer. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 185\u2013204, Humana Press, Totowa, NJ, 2002."},{"issue":"11","key":"9_CR15","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/carcin\/15.11.2395","volume":"15","author":"K El-Bayoumy","year":"1994","unstructured":"El-Bayoumy K. Evaluation of chemoprevention agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 15 (11): 2395\u20132420, 1994.","journal-title":"Carcinogenesis"},{"key":"9_CR16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/bjc.1977.132","volume":"35","author":"A Bennett","year":"1977","unstructured":"Bennett A, Tacca MD, Stamford IF, Zebro T. Prostaglandins from tumors of human large bowel. Br J Cancer 35: 881\u20134, 1977.","journal-title":"Br J Cancer"},{"key":"9_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/gut.28.3.315","volume":"28","author":"A Bennett","year":"1987","unstructured":"Bennett A, Civier A, Hensby CN, et al. Measurement of arachidonate and its metabolities extracted from human normal and malignant gastrointestinal tissues. Gut 28: 315\u20138, 1987.","journal-title":"Gut"},{"key":"9_CR18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/BF02051919","volume":"33","author":"T Narisawa","year":"1990","unstructured":"Narisawa T, Kusaka H, Yamazaki Y, Takahashi M, Koyama H, Koyama K, et al. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 33: 840\u20135, 1990.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"9_CR19","first-page":"1061","volume":"64","author":"PH Rolland","year":"1980","unstructured":"Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64 (5): 1061\u201370, 1980.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0952-3278(92)90090-6","volume":"45","author":"WJ Kort","year":"1991","unstructured":"Kort WJ, Bijma AM, van Dam JJ, vd Ham AC, Hekking JM, Ingh HF, Meijer WS, van Wilgenburg MGM, Zijlstra FJ. Eicosanoids in breast cancer patients before and after mastectomy. Prostaglandins Leukotrienes and Essential Fatty Acids, 45: 319\u2013327, 1991.","journal-title":"Prostaglandins Leukotrienes and Essential Fatty Acids"},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0952-3278(96)90075-7","volume":"54","author":"G Ara","year":"1996","unstructured":"Ara G, Teicher BA. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostagland, Leuk and Essent Fatty Acids 54: 3\u201316, 1996.","journal-title":"Prostagland, Leuk and Essent Fatty Acids"},{"key":"9_CR22","first-page":"74","volume":"20","author":"GJ Kelloff","year":"1994","unstructured":"Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, Greenwald P, Temple RJ. Guidance for development of chemopreventive agents, Clinical Development Plan: Aspirin, J Cellular Biochemistry, Suppl. 20: 74\u201383, 1994.","journal-title":"Clinical Development Plan: Aspirin, J Cellular Biochemistry, Suppl."},{"issue":"3","key":"9_CR23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/scientificamerican0996-96","volume":"275","author":"P Greenwald","year":"1996","unstructured":"Greenwald P. Chemoprevention of cancer. Scientific American 275 (3): 96\u2013100, 1996.","journal-title":"Scientific American"},{"issue":"1","key":"9_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/canjclin.45.1.31","volume":"45","author":"P Greenwald","year":"1995","unstructured":"Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer Journal for Clinicians 45 (1): 31\u201349, 1995.","journal-title":"CA Cancer Journal for Clinicians"},{"issue":"7","key":"9_CR25","first-page":"1651","volume":"52","author":"CW Boone","year":"1992","unstructured":"Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy. Cancer Res 52 (7): 1651\u20131659, l992.","journal-title":"Cancer Res"},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0016-5085(95)90296-1","volume":"109","author":"CE Eberhart","year":"1995","unstructured":"Eberhart CE, Dubois RN. Eicosanids and the gastrointestinal gract. Gastroenterology 109: 285\u2013301, 1995.","journal-title":"Gastroenterology"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","volume":"90","author":"JA Mitchell","year":"Dec 1994","unstructured":"Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693\u201311697, Dec 1994.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9_CR28","first-page":"5575","volume":"52","author":"LJ Marnett","year":"1992","unstructured":"Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575\u20135589, 1992.","journal-title":"Cancer Res"},{"key":"9_CR29","first-page":"1103","volume":"70","author":"M Pollard","year":"1983","unstructured":"Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70: 1103\u20135, 1983.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR30","first-page":"6471","volume":"49","author":"M Pollard","year":"1989","unstructured":"Pollard M, Luckert PH. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471\u20133, 1989.","journal-title":"Cancer Res"},{"key":"9_CR31","first-page":"5340","volume":"47","author":"BS Reddy","year":"1987","unstructured":"Reddy BS, Maruyama H, Kelloff G. Dose related inhibition of colon carcinogenisis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340\u20136, 1987.","journal-title":"Cancer Res"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/carcin\/13.6.1019","volume":"13","author":"BS Reddy","year":"1992","unstructured":"Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019\u201323, 1992.","journal-title":"Carcinogenesis"},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jnci\/73.2.457","volume":"73","author":"RA Karmali","year":"1984","unstructured":"Karmali RA, Marsh J, Fuchs C. Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst 73: 457\u2013461, 1984.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/1-59259-302-X:03","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"RA Karmali","year":"2002","unstructured":"Karmali RA. Dietary fatty acids, COX-2 blockade, and carcinogenesis. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 3\u201312, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1385\/1-59259-302-X:99","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"HM Schuller","year":"2002","unstructured":"Schuller HM. The role of cyclooxygenase-2 in the prevention and therapy of lung cancer. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 99\u2013116, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pros.2990180306","volume":"18","author":"DP Rose","year":"1991","unstructured":"Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18: 243\u2013254, 1991.","journal-title":"Prostate"},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1385\/1-59259-302-X:279","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"GJ Kelloff","year":"2002","unstructured":"Kelloff GJ, Steele VE, Sigman CC. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 279\u2013300, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1385\/1-59259-302-X:71","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"BS Reddy","year":"2002","unstructured":"Reddy BS, Rao CV. Role of synthetic and naturally occurring cyclooxygenase inhibitors in colon cancer prevention. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 71\u201383, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR39","first-page":"409","volume":"58","author":"T Kawamori","year":"1998","unstructured":"Kawamori T, Rao CV, Siebert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase 2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409\u2013412, 1998.","journal-title":"Cancer Res"},{"key":"9_CR40","first-page":"2101","volume":"60","author":"RE Harris","year":"2000","unstructured":"Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a specific cyclooygenase-2 (COX-2) inhibitor. Cancer Res 60: 2101\u20132103, 2000.","journal-title":"Cancer Res"},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1385\/1-59259-302-X:85","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"HM Abou-Issa","year":"2002","unstructured":"Abou-Issa HM, Alshafie GA, Harris RE. Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 85\u201398, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.190.4.445","volume":"190","author":"SJ Shiff","year":"1999","unstructured":"Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal anti-inflammatory drugs (NSAIDs). J Exp Med 190: 445\u2013450, 1999.","journal-title":"J Exp Med"},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/erc.0.0080097","volume":"8","author":"LR Howe","year":"2001","unstructured":"Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 8: 97\u2013114, 2001.","journal-title":"Endocrine-Related Cancer"},{"issue":"4","key":"9_CR44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1054\/mehy.1998.0009","volume":"52","author":"RE Harris","year":"1999","unstructured":"Harris RE, Robertson FM, Farrar WB, Brueggemeier RW. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP-19): an extension of the dietary fat hypothesis of breast cancer. Medical Hypotheses 52 (4): 292\u2013293, 1999.","journal-title":"Medical Hypotheses"},{"issue":"12","key":"9_CR45","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1210\/endo.137.12.8940410","volume":"137","author":"Y Zhao","year":"1996","unstructured":"Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19(aromatase) gene. Endocrinology 137 (12): 5739\u20135742, 1996.","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"9_CR46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(99)00050-6","volume":"140","author":"RW Brueggemeier","year":"1999","unstructured":"Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Letters 140 (1\u20132): 27\u201335, l999.","journal-title":"Cancer Letters"},{"issue":"6","key":"9_CR47","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1074\/jbc.272.6.3406","volume":"272","author":"JM Lehmann","year":"1997","unstructured":"Lehmann JM, Lenhard Jm, Oliver BB, Ringold GM, Kliewer SA. Perioxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 272 (6): 3406\u20133410, 1997.","journal-title":"J Biol Chem"},{"issue":"9","key":"9_CR48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0006-2952(97)00651-5","volume":"55","author":"HM Schuller","year":"1998","unstructured":"Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 55 (9): 1377\u20131384, l998.","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"9_CR49","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/0006-2952(89)90112-3","volume":"38","author":"HM Schuller","year":"1989","unstructured":"Schuller HM. Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. Biochem Pharmacol 38 (20): 3439\u20133442, l989.","journal-title":"Biochem Pharmacol"},{"issue":"2480","key":"9_CR50","first-page":"370","volume":"38","author":"FS Joarder","year":"1997","unstructured":"Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, Harris RE. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague-Dawley rats, Proc Amer Assoc Cancer Res 38 (2480): 370, 1997.","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"9_CR51","first-page":"3031","volume":"19","author":"GA Alshafie","year":"1999","unstructured":"Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Research 19: 3031\u20133036, l999.","journal-title":"Anticancer Research"},{"key":"9_CR52","first-page":"3559","volume":"43","author":"CA Carter","year":"1983","unstructured":"Carter CA, Milholland RJ, Shea W, Ip MM. Effect of prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 43: 3559\u20133562, 1983.","journal-title":"Cancer Res"},{"key":"9_CR53","first-page":"2416","volume":"44","author":"AM Fulton","year":"1984","unstructured":"Fulton AM. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 44: 2416\u20132420, 1984.","journal-title":"Cancer Res"},{"issue":"721","key":"9_CR54","first-page":"182","volume":"30","author":"MM Ip","year":"1989","unstructured":"Ip MM, Mazzer C, Watson D, Ip C. The effect of eicosanoid synthesis inhibitors on DMBA-induced rat mammary carcinogenesis. Proc Amer Assoc Cancer Res, 30 (721): 182, 1989.","journal-title":"Proc Amer Assoc Cancer Res"},{"issue":"1","key":"9_CR55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0952-3278(92)90098-4","volume":"45","author":"PP Lee","year":"1992","unstructured":"Lee PP, Ip MM. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostalgand Leuk Essent Fatty Acids 45 (1): 21\u201331, 1992.","journal-title":"Prostalgand Leuk Essent Fatty Acids"},{"key":"9_CR56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcb.240560905","volume":"20","author":"VE Steele","year":"1994","unstructured":"Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DK, Pereira MA, Crowell JA, Bagheri D. Sigman CC, Boone CS, Kelloff G Jr. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI drug chemoprevention drug development program. J Cell Biol Suppl 20: 32\u201353, l994.","journal-title":"J Cell Biol Suppl"},{"key":"9_CR57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/pmed.1995.1022","volume":"24","author":"RE Harris","year":"1995","unstructured":"Harris RE, Namboodiri KK, Stellman SD, Wynder EL. Breast cancer and NSAID use: Heterogeneity of effect in a case-control study. Preventive Medicine 24: 119\u2013120, 1995.","journal-title":"Preventive Medicine"},{"key":"9_CR58","first-page":"591","volume":"2","author":"RE Harris","year":"1995","unstructured":"Harris RE, Namboodiri KK, Farrar WB. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncology Reports 2: 591\u2013592, 1995.","journal-title":"Oncology Reports"},{"key":"9_CR59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00001648-199603000-00017","volume":"7","author":"RE Harris","year":"1996","unstructured":"Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203\u2013205, 1996.","journal-title":"Epidemiology"},{"key":"9_CR60","first-page":"71","volume":"6","author":"RE Harris","year":"1999","unstructured":"Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncology Reports 6: 71\u201373, 1999.","journal-title":"Oncology Reports"},{"key":"9_CR61","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascensco JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative. Cancer Research 63: 6096\u20136101, 2003.","journal-title":"Cancer Research"},{"issue":"2","key":"9_CR62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/aje\/kwi182","volume":"162","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer, the Case-Control Surveillance Study revisited. Am J Epidemiol 162 (2): 165\u2013170, 2005.","journal-title":"Am J Epidemiol"},{"key":"9_CR63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pros.2990080110","volume":"8","author":"M Pollard","year":"1986","unstructured":"Pollard M, Luckert PH. The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells. Prostate 8: 81\u201386, 1986.","journal-title":"Prostate"},{"key":"9_CR64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","volume":"42","author":"S Gupta","year":"2000","unstructured":"Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73\u201378, 2000.","journal-title":"Prostate"},{"key":"9_CR65","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C","volume":"89","author":"R Yoshimura","year":"2000","unstructured":"Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Charui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenease-2 in prostate carcinoma. Cancer 89: 589\u2013596, 2000.","journal-title":"Cancer"},{"issue":"2","key":"9_CR66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/bbrc.1997.6799","volume":"235","author":"J Ghosh","year":"1997","unstructured":"Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochemical and Biophysiological Research Community 235 (2): 418\u2013423, l997.","journal-title":"Biochemical and Biophysiological Research Community"},{"key":"9_CR67","first-page":"169","volume":"7","author":"JE Nelson","year":"2000","unstructured":"Nelson JE, Harris RE. Inverse association of prostate cancer and nonsteroidal anti-inflammatory drugs (NSAIDs): results of a case control study. Oncology Reports 7: 169\u2013170, 2000.","journal-title":"Oncology Reports"},{"key":"9_CR68","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0016-5085(91)90519-Q","volume":"101","author":"D Labayle","year":"1991","unstructured":"Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Troussett M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635\u2013639, 1991.","journal-title":"Gastroenterology"},{"key":"9_CR69","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","volume":"328","author":"FM Giardiello","year":"1993","unstructured":"Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus JA. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313\u20136, 1993.","journal-title":"N Engl J Med"},{"key":"9_CR70","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/bjs.1800801244","volume":"80","author":"KP Nugent","year":"1993","unstructured":"Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80: 1618\u20139, 1993.","journal-title":"Br J Surg"},{"key":"9_CR71","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jnci\/85.11.912","volume":"85","author":"ER Greenberg","year":"1993","unstructured":"Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 85: 912\u2013916, 1993.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.307.6899.285","volume":"307","author":"RF Logan","year":"1993","unstructured":"Logan RF, Litte J, Hawtin PG, Hardcastle JD. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening program. BMJ 307: 285\u2013289, 1993.","journal-title":"BMJ"},{"key":"9_CR73","first-page":"703","volume":"4","author":"M Martinez","year":"1995","unstructured":"Martinez M, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 4: 703\u2013707, 1995.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9_CR74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0016-5085(98)70526-8","volume":"114","author":"RS Sandler","year":"1998","unstructured":"Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441\u2013448, 1998.","journal-title":"Gastroenterology"},{"key":"9_CR75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000007745","volume":"61","author":"B Breuer-Katschinski","year":"2000","unstructured":"Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr, Breuer N, et al. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 61: 129\u2013134, 2000.","journal-title":"Digestion"},{"key":"9_CR76","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199112053252301","volume":"325","author":"M Thun","year":"1991","unstructured":"Thun M, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Eng J Med 325: 1593\u20131596, l991.","journal-title":"N Eng J Med"},{"key":"9_CR77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/1-59259-302-X:35","volume-title":"COX-2 Blockade in Cancer Prevention and Therapy","author":"M Thun","year":"2002","unstructured":"Thun M, Henley SJ. Epidemiology of nonsteroidal anti-inflammatory drugs and colorectal cancer. In: RE Harris (ed), COX-2 Blockade in Cancer Prevention and Therapy, pp 35\u201355, Humana Press, Totowa, NJ, 2002."},{"key":"9_CR78","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","volume":"107","author":"CE Eberhart","year":"1994","unstructured":"Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cycloxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183\u20131188, l994.","journal-title":"Gastroenterology"},{"key":"9_CR79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0016-5085(95)90296-1","volume":"109","author":"CE Eberhart","year":"1995","unstructured":"Eberhart CE, Dubois RN. Eicosanids and the gastrointestinal gract. Gastroenterology 109: 285\u2013301, 1995.","journal-title":"Gastroenterology"},{"key":"9_CR80","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RK, Wallace MB, Hawk E, Gordon G, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl J Med 342: 1946\u201352. 2000.","journal-title":"New Engl J Med"},{"issue":"19","key":"9_CR81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","volume":"348","author":"RS Sandler","year":"2003","unstructured":"Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med 348 (19): 883\u2013390, 2003.","journal-title":"New Engl J Med"},{"issue":"20","key":"9_CR82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (20): 252\u2013266, 2002.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR83","first-page":"1393","volume":"19","author":"A Castonguay","year":"1997","unstructured":"Castonguay A, Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 19: 1393\u20131400, 1997.","journal-title":"Carcinogenesis"},{"key":"9_CR84","first-page":"5354","volume":"58","author":"N Rioux","year":"1998","unstructured":"Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigeneis in A\/J mice by acteylsalicaylic acid and NS-398. Cancer Res 58: 5354\u20135360, 1998.","journal-title":"Cancer Res"},{"issue":"3","key":"9_CR85","first-page":"445","volume":"19","author":"HM Schuller","year":"2001","unstructured":"Schuller HM, Plummer HK III, Bochsler PN, Dudric P, Bell JL, Harris RE. Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. Int J Oncol 19(3): 445\u2013449, 2001.","journal-title":"Int J Oncol"},{"issue":"6618","key":"9_CR86","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed): 296 (6618): 313\u2013316, 1988.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"9_CR87","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00001648-199403000-00003","volume":"5","author":"DM Schreinemachers","year":"1994","unstructured":"Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138\u2013146, 1994.","journal-title":"Epidemiology"},{"key":"9_CR88","first-page":"693","volume":"9","author":"RE Harris","year":"2002","unstructured":"Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by nonsteroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9: 693\u2013695, 2002.","journal-title":"Oncology Reports"},{"key":"9_CR89","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/oxfordjournals.aje.a112395","volume":"105","author":"SD Walter","year":"1977","unstructured":"Walter SD. Determination of significant relative risks and optimal sampling procedures in prospective and retrospective comparative studies of various sample sizes. Am J Epidemiol 105: 387\u2013397, l977.","journal-title":"Am J Epidemiol"},{"key":"9_CR90","volume-title":"Case Control Studies: Design, Conduct, Analysis","author":"JJ Schlesselman","year":"1982","unstructured":"Schlesselman JJ. Case Control Studies: Design, Conduct, Analysis. Oxford University Press, New York, NY, 1982."},{"key":"9_CR91","unstructured":"Harrell F. Logistic Regression Procedure. Statistical Analysis System (SAS), 2005."},{"issue":"21","key":"9_CR92","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D. Burgo-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schuitzer TJ. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (21): 1520\u20131528, 2000.","journal-title":"N Engl J Med"},{"issue":"10","key":"9_CR93","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (10): 1247\u20131255, 2000.","journal-title":"JAMA"},{"key":"9_CR94","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"LS Simon","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, Kivitz AJ, Kipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. Journal of the American Medical Association 282: 1921\u20131928, 1999.","journal-title":"Journal of the American Medical Association"},{"key":"9_CR95","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Journal of the American Medical Association 282: 1929\u20131933, 1999.","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"9_CR96","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gut.48.3.339","volume":"48","author":"AA Shah","year":"2001","unstructured":"Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ, Bjarnason I. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 48 (3): 339\u2013346, 2001.","journal-title":"Gut"},{"issue":"8","key":"9_CR97","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (8): 954\u2013959, 2001.","journal-title":"Jama"},{"key":"9_CR98","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.306.5695.384","volume":"306","author":"J Couzin","year":"2004","unstructured":"Couzin J. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 306: 384\u2013385, 2004.","journal-title":"Science"},{"issue":"11","key":"9_CR99","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352 (11): 1092\u20131102.","journal-title":"N Engl J Med"},{"issue":"11","key":"9_CR100","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352 (11), 1071\u20131080, 2005.","journal-title":"N Engl J Med"},{"key":"9_CR101","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1126\/science.306.5702.1673","volume":"306","author":"J Couzin","year":"2004","unstructured":"Couzin J. Clinical Trials: Nail-biting time for trials of drugs. Science, 306: 1673\u20131675, 2004.","journal-title":"Science"},{"issue":"4","key":"9_CR102","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","volume":"89","author":"WB White","year":"2002","unstructured":"White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89 (4): 425\u2013430, 2002.","journal-title":"Am J Cardiol"},{"issue":"4","key":"9_CR103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib. Am J Cardiol 92 (4): 411\u2013418, 2003.","journal-title":"Am J Cardiol"},{"key":"9_CR104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1126\/science.308.5719.203a","volume":"308","author":"RE Harris","year":"2005","unstructured":"Harris RE. Does the dose make the poison? Science 308, 203, 2005.","journal-title":"Science"},{"key":"9_CR105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2407-6-27","volume":"6","author":"RE Harris","year":"2006","unstructured":"Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6: 27, 2006.","journal-title":"BMC Cancer"}],"container-title":["Subcellular Biochemistry","Inflammation in the Pathogenesis of Chronic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/1-4020-5688-5_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T20:47:02Z","timestamp":1558126022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/1-4020-5688-5_9"}},"subtitle":["Results of case control studies"],"short-title":[],"issued":{"date-parts":[[2007]]},"ISBN":["9781402056871","9781402056888"],"references-count":105,"URL":"https:\/\/doi.org\/10.1007\/1-4020-5688-5_9","relation":{},"ISSN":["0306-0225"],"issn-type":[{"value":"0306-0225","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]}}}